TRANDOLAPRIL Drug Patent Profile
Which patents cover Trandolapril, and when can generic versions of Trandolapril launch?
Trandolapril is a drug marketed by Aurobindo Pharma, Chartwell Molecular, Epic Pharma, Epic Pharma Llc, Invagen Pharms, Lupin, Pharmazone, Pharmobedient, Teva Pharms, Watson Labs, and Glenmark Pharms Ltd. and is included in eleven NDAs.
The generic ingredient in TRANDOLAPRIL is trandolapril; verapamil hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trandolapril
A generic version of TRANDOLAPRIL was approved as trandolapril; verapamil hydrochloride by GLENMARK PHARMS LTD on May 5th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TRANDOLAPRIL?
- What are the global sales for TRANDOLAPRIL?
- What is Average Wholesale Price for TRANDOLAPRIL?
Summary for TRANDOLAPRIL
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Clinical Trials: | 18 |
| Drug Prices: | Drug price information for TRANDOLAPRIL |
| DailyMed Link: | TRANDOLAPRIL at DailyMed |
Recent Clinical Trials for TRANDOLAPRIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 4 |
| Hospital Authority, Hong Kong | Phase 4 |
| Assaf-Harofeh Medical Center |
Pharmacology for TRANDOLAPRIL
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TRANDOLAPRIL
Paragraph IV (Patent) Challenges for TRANDOLAPRIL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MAVIK | Tablets | trandolapril | 1 mg, 2 mg and 4 mg | 020528 | 1 | 2004-10-04 |
